The consensus in modern medicine is comforting: precision beats one-size-fits-all. Genetic testing, biomarker screening, tailored drug protocols. Personalize everything, and outcomes improve. Patients get better care. Medicine becomes smarter.
The better question is not whether personalization works. It's what this shift breaks for people who can't access it.
Personalized medicine assumes infrastructure. It assumes lab capacity, genetic counseling, data systems, insurance coverage, and follow-up monitoring. It assumes patients can afford to wait for results, take time off work for testing, and navigate the paperwork. Most importantly, it assumes trust in the medical system doing the personalizing.
That last assumption is crucial and fragile.
Recent headlines touching on medical ethics remind us why. Historical wrongs in medical research don't disappear because we've renamed our practices. They linger in collective memory and in rational hesitation. When new screening protocols, genetic studies, or vaccine trials get rolled out with promises of precision benefit, skepticism isn't a bug. It's a feature of informed consent.
The risk is real: personalized medicine risks becoming a two-tier system. Those with resources, health literacy, and trust in institutions get customized protocols. Everyone else gets whatever's standardized, available, and affordable. That's not personalization. That's stratification dressed up as progress.
Consider what happens in a rural clinic without genetic sequencing capability. A patient presents with a condition that responds differently based on genetic variants. The personalized approach says: test first, then treat. But testing costs money upfront, requires transport to a distant facility, and delays treatment by weeks. The standardized approach says: try this medication that works for most people. It's not optimal. It's practical.
Which patient gets better care? That depends entirely on whether we think "better" means statistically superior outcomes or outcomes that actually reach the patient.
Personalized medicine also creates a new form of medical gatekeeping. Specialists and high-resource centers become the places where truly personalized care happens. Primary care providers become technicians following protocols designed elsewhere. This isn't inherently bad. But it concentrates medical decision-making power away from frontline clinicians who know their patients best.
There's also the data question, which deserves more skepticism than it typically gets. Personalization requires data. Lots of it. Genetic databases, treatment outcomes, side effect profiles. That data comes from people. And historically, those databases have been skewed toward certain populations, certain geographies, certain bodies. A personalization algorithm trained mostly on data from wealthy, white, urban populations will personalize care differently for rural, Black, or immigrant patients. It will feel precise while being systematically biased.
None of this argues against personalized medicine. It argues for humility about what it solves and what it obscures.
The honest version of precision medicine looks like this: where resources and infrastructure exist, personalization can improve outcomes. Where they don't, it can worsen inequality by creating a new standard of care that some can never meet. The goal shouldn't be personalizing medicine for those who can afford it. It should be ensuring that whoever designs and deploys personalized approaches is actively managing the risk of deepening gaps.
That requires asking harder questions than "does personalization work?" It requires asking: "For whom does it work? For whom does it fail? And what are we building that assumes people have what we have?"
Those questions are less comfortable than consensus. They're also less avoidable.